Radiopharm Theranostics Limited

RAD

AU0000181851

Pharmaceuticals

Market Closed - Australian S.E. Other stock markets 23:53:38 2024-05-09 EDT			5-day change	1st Jan Change
0.04 ^AUD	+2.56%		+11.11%	-45.95%

05-08	Radiopharm Theranostics to be Featured in Healthcare Events Hosted by B. Riley Securities	MT
02-29	Radiopharm Theranostics Doses First Patient in Pancreatic Cancer Imaging Study	MT

Radiopharm welcomes positive guidance from FDA to advance Pivalate

May 31, 2023 at 11:01 am

(via NewsDirect)

Radiopharm Theranostics Ltd (ASX:RAD) CEO Riccardo Canevari speaks with Proactive after the company completed a positive pre-Investigational New Drug (IND) meeting with the US Food and Drug Administration (FDA) for its proprietary imaging agent, F18-pivalate (RAD 101). He says it’s a significant milestone towards Radiopharm’s IND application for late-stage clinical trials. In October 2022, positive data from the Imperial College of London’s Phase IIa imaging trial of RAD 101 in patients with brain metastases showed significant tumour uptake consistent with and independent from the tumour of origin.

Contact Details

Proactive Investors

Jonathan Jackson

+61 413 713 744

jonathan@proactiveinvestors.com

Latest news about Radiopharm Theranostics Limited

Radiopharm Theranostics to be Featured in Healthcare Events Hosted by B. Riley Securities	05-08	MT
Radiopharm Theranostics Doses First Patient in Pancreatic Cancer Imaging Study	02-29	MT
Radiopharm Theranostics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	02-28	CI
Radiopharm Theranostics Receives AU$1.9 Million Advance on R&D Tax Rebate	02-20	MT
Radiopharm Secures Investment from US-based Lind Partners; Shares Decline 6%	02-06	MT
Radiopharm Theranostics Raises AU$1.7 Million Via Shortfall Placement	01-23	MT
Radiopharm Theranostics Secures Ethics Approval for Second Lung Cancer Trial Site	12-26	MT
Radiopharm Theranostics to Start Phase One Lung Cancer Therapy Trial	12-25	MT
Radiopharm Theranostics Raises AU$2.1 Million Via Entitlement Offer	12-08	MT
28,046,696 Options of Radiopharm Theranostics Limited are subject to a Lock-Up Agreement Ending on 25-NOV-2023.	11-24	CI
100,000,000 Ordinary Shares of Radiopharm Theranostics Limited are subject to a Lock-Up Agreement Ending on 25-NOV-2023.	11-24	CI
Radiopharm Theranostics Secures AU$5 Million R&D Tax Rebate for Fiscal Year 2023; Shares Rise 4%	11-20	MT
Radiopharm Theranostics Secures US FDA Approval for Phase 1 Pancreatic Cancer Diagnostic Trial	23-10-17	MT
Radiopharm Theranostics Secures Ethics Approval for Lung Cancer Trial; Shares Rise 4%	23-10-08	MT
Radiopharm Theranostics Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-30	CI
Radiopharm Theranostics Secures US FDA Guidance for Clinical Trial of Imaging Drug in Brain Metastasis	23-05-29	MT
Radiopharm Theranostics Receives FDA Orphan Drug Designation for Trivehexin (RAD 301) in Pancreatic Cancer	23-05-09	CI
Radiopharm Theranostics Receives US FDA Orphan Drug Designation for Pancreatic Cancer Medication	23-05-09	MT
Radiopharm Theranostics Receives AU$1.6 Million R&D Tax Refund; Shares Fall 3%	23-03-27	MT
Radiopharm Theranostics, GenesisCare Partner to Develop Novel Radiopharmaceuticals in Australia	23-03-26	MT
Radiopharm Theranostics Limited and GenesisCare to Develop Novel Radiopharmaceuticals	23-03-26	CI
Radiopharm Theranostics Appoints Dr. Ken Herrmann to the Scientific Advisory Board	23-03-03	CI
Radiopharm Theranostics Acquiring Pharma15 for AU$6 Million	23-03-03	MT
Radiopharm Theranostics Limited entered into a binding agreement to acquire Pharma15 Corporation.	23-03-02	CI
Radiopharm Theranostics Limited Reports Earnings Results for the Half Year Ended December 31, 2022	23-02-28	CI

Chart Radiopharm Theranostics Limited

Duration

Period

More charts

Company Profile

Radiopharm Theranostics Limited is an Australia-based clinical-stage radiotherapeutics company. The Company is focused on the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical need. The Company has a pipeline of six platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer, in pre-clinical and clinical stages of development. The clinical program includes one Phase II and three Phase I trials in a variety of solid tumor cancers including breast, kidney and brain. The Company's technologies include Nano-mAbs, Pivalate, AVB6 Integrin, PSA-mAb, DUNP19 and PTPu. Nano-mAbs is a novel radiopharmaceutical platform made using genetic engineered camelid derived single domain antibodies (sdAb) labeled with a radioisotope of therapeutic radiation. Pivalate is an 18F-FPIA radiotracer, based on a short chain carbohydrate that utilizes the early steps of fatty acid oxidation.

Sector

Pharmaceuticals

Calendar

2024-09-25 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.0264 USD

Average target price

0.317 USD

Spread / Average Target

+1,100.24%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
RADIOPHARM THERANOSTICS LIMITED	-45.95%	11.64M
ELI LILLY AND COMPANY	+30.66%	695B
NOVO NORDISK A/S	+26.51%	568B
JOHNSON & JOHNSON	-4.61%	361B
MERCK & CO., INC.	+19.69%	330B
ABBVIE INC.	+3.82%	283B
ASTRAZENECA PLC	+16.70%	239B
NOVARTIS AG	+8.78%	204B
ROCHE HOLDING AG	-7.93%	198B
AMGEN INC.	+8.08%	168B

Other Pharmaceuticals

Radiopharm Theranostics Limited

Equities

RAD

AU0000181851

Pharmaceuticals

Radiopharm welcomes positive guidance from FDA to advance Pivalate

Contact Details

Latest news about Radiopharm Theranostics Limited

Chart Radiopharm Theranostics Limited

Company Profile

Income Statement Evolution

Analysts' Consensus

EPS Revisions

Quarterly revenue - Rate of surprise

Sector Other Pharmaceuticals